ReviewDegenerative neurological and neuromuscular disease2020
Re-Evaluating the Use of IFN-β and Relapsing Multiple Sclerosis: Safety, Efficacy and Place in Therapy.
Review in Degenerative neurological and neuromuscular disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- From Demyelination to Intervention: Natural Compounds as Emerging Therapeutic Targets in Multiple Sclerosis Neuroinflammation.Journal of immunology research · 2026Review
- Targeting Lifestyle in CNS Inflammatory Demyelinating Diseases: Insights from Diet and Exercise as Potential Disease Modifiers.Brain sciences · 2025Review
- Post-Translational Modified Neoantigens in Autoimmune Diseases: Challenges of Immune Tolerance.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives.Neurology and therapy · 2024Review
- Berberine: A natural modulator of immune cells in multiple sclerosis.Immunity, inflammation and disease · 2024Review
- Exploring blood transcriptomic signatures in patients with herpes zoster and postherpetic neuralgia.Frontiers in cellular and infection microbiology · 2024Article
- Bioelectronic cell-based device provides a strategy for the treatment of the experimental model of multiple sclerosis.Journal of controlled release : official journal of the Controlled Release Society · 2022Article
- Exploiting natural antiviral immunity for the control of pandemics: Lessons from Covid-19.Cytokine & growth factor reviews · 2022Review
- Severe Late-Onset Drug-Induced Immune Thrombocytopenia Following IFNCase reports in hematology · 2022Article
- Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target.Frontiers in immunology · 2022Review
- Outcomes of COVID-19 among patients treated with subcutaneous interferon beta-1a for multiple sclerosis.Multiple sclerosis and related disorders · 2021Article
- Shared and Unique Features of Human Interferon-Beta and Interferon-Alpha Subtypes.Frontiers in immunology · 2020Review
- Predictors of high- versus low-intensity first-line multiple sclerosis treatments.Multiple sclerosis journal - experimental, translational and clinicalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The advent of interferon therapy for the treatment of multiple sclerosis (MS) was a massive advancement in the field and changed the course of the disease. While the exact mechanism of interferon therapy in MS is unknown, disease control is likely mediated by reducing Th1 and Th17 cells while increasing regulatory T cells and altering the cytokine profile. Interferon therapy not only gave physicians and patients an evidence-based treatment option to treat MS by decreasing relapses and the accrual of disability but it also provided valuable insight into disease pathophysiology that allowed for the development of further treatments. Currently, there are 18 disease-modifying therapies available for the treatment of MS with varying efficacies, routes of administration, and mechanisms. As treatment options in the field have evolved, interferon therapy is less commonly prescribed as first-line therapy, because the newer therapies are more effective and better tolerated. That being said, interferons still have a place in the field in both clinical practice and clinical trial research. In this review, we will summarize the safety and efficacy of interferon therapy and discuss its current place in MS care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.